Shelton Capital Management’s Editas Medicine EDIT Stock Holding History

Shelton Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-135,200	Closed	-$1.2M	–	744
2022 Q4	$1.2M	Sell	135,200 -10,200	-7%	-$112K	0.13%	193
2022 Q3	$1.78M	Sell	145,400 -24,600	-14%	-$383K	0.08%	207
2022 Q2	$2.01M	Hold	170,000	–	–	0.09%	209
2022 Q1	$3.23M	Sell	170,000 -10,000	-6%	-$186K	0.12%	178
2021 Q4	$4.78M	Hold	180,000	–	–	0.17%	136
2021 Q3	$7.39M	Buy	180,000 +10,000	+6%	+$548K	0.29%	80
2021 Q2	$9.63M	Buy	170,000 +38,000	+29%	+$1.4M	0.36%	60
2021 Q1	$5.54M	Buy	132,000 +78,000	+144%	+$4.44M	0.19%	114
2020 Q4	$3.79M	Buy	54,000 +19,000	+54%	+$781K	0.17%	127
2020 Q3	$982K	Hold	35,000	–	–	0.04%	349
2020 Q2	$1.03M	Hold	35,000	–	–	0.06%	242
2020 Q1	$694K	Buy	35,000 +9,500	+37%	+$240K	0.05%	248
2019 Q4	$755K	Hold	25,500	–	–	0.04%	266
2019 Q3	$580K	Buy	25,500 +15,000	+143%	+$372K	0.03%	311
2019 Q2	$260K	Buy	+10,500	New	+$251K	0.02%	622

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Shelton Capital Management's EDIT Position: Q1 2023 in Review

Shelton Capital Management sold out of Editas Medicine (EDIT) in Q1 2023, closing a stake of 135,200 shares — an estimated $1.2M sold.

Shelton Capital Management first reported a position in EDIT in Q2 2019 and held it in 15 quarters. The position peaked at $9.63M in Q2 2021. 234 funds tracked by Wall St. Rank hold EDIT as of Q1 2023.

Shelton Capital Management reported no remaining Editas Medicine position as of Q1 2023 after selling out during the quarter.
Shelton Capital Management sold 135,200 Editas Medicine shares in Q1 2023, an estimated $1.2M.
Shelton Capital Management first reported a position in Editas Medicine in Q2 2019 and held it in 15 quarters.
Shelton Capital Management's Editas Medicine position peaked at $9.63M in Q2 2021.
234 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2023.

Based on Shelton Capital Management's 13F filing for Q1 2023, filed 11 May 2023.